Gilead to stop late-stage study of Covid-19 treatment
A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

Gilead Sciences said on Monday it had decided to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized patients with Covid-19.

The company said it no longer believes that developing a multiple-day injection that requires administration in a healthcare setting addresses an unmet need for non-hospitalized patients.

The decision to stop the study is not due to efficacy or safety concerns, Gilead said.